Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pharming initiates Phase I study in ageing diseases
The Phase I trial that is now being conducted consists of a combined single and multiple dose escalating clinical study in healthy volunteers. By studying the pharmacokinetics and
The Phase I trial that is now being conducted consists of a combined single and multiple dose escalating clinical study in healthy volunteers. By studying the pharmacokinetics and
Aplenzin is an alcohol-resistant formulation of a new bupropion salt and has been approved in 174mg, 348mg, and 522mg extended-release tablets. The 522mg dosage strength provides patients requiring
In connection with the acquisition, James Pachence, Virium’s president and CEO has been appointed CEO of the combined company and David Luci has been named president & chief
The primary objective of this registration-directed Phase IIb trial is to demonstrate the efficacy of PTC124 as measured by improvements in the walking ability of patients with this
Under the terms of the private investment, Champions Biotechnology issued 1,428,572 restricted shares of the company’s common stock at $1.75 per share. There were no fees or other
The Phase III study compared renzapride 4mg once a day, renzapride 2mg twice daily and placebo, dosed for 12 weeks, in women with irritable bowel syndrome (IBS-C). Approximately
CuraGen will receive $26 million in cash and five million shares of TopoTarget common stock, currently valued at approximately $13 million, and $6 million in potential commercial milestone
ViziLite Eyewear is reusable filtered eyewear to be worn by a health care professional to eliminate ambient light while performing an oral exam under chemiluminescence when a darkened
Calgenex was acquired for 22 million shares of restricted common stock. Jeff Roman, CEO and president of PanGenex, said: “Completing the acquisition of Calgenex allows us to aggressively
The NB-301 clinical trial is a placebo-controlled, 56-week study intended to analyze the efficacy, safety and tolerability of two doses of Contrave in generally healthy obese patients. This